Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems

Metabolic associated fatty liver disease (MAFLD) affects 20–30% of the worldwide population and is becoming the most common cause of chronic liver disease, cirrhosis and hepatocellular carcinoma (HCC). MAFLD is the hepatic expression of metabolic dysfunction correlated with a variety of metabolic comorbidities including obesity, dyslipidemia, hypertension and type 2 diabetes (T2DM). Obesity, altered gut permeability, chronic inflammation and dysbiosis related to MAFLD might predispose patients with cirrhosis to the development of acute-on-chronic liver failure (ACLF); however, this relationship remains unclear. ACLF is a syndrome with high short-term mortality, presenting with acute hepatic decompensation associated with organ failures in patients with underlying chronic liver disease with or without an identifiable precipitating event. While this syndrome can occur in any patient with cirrhosis, the increasing prevalence of cirrhosis due to MAFLD is of great concern because, in a recent analysis, MAFLD was the fastest rising cause of cirrhosis associated with ACLF among patients listed for LT in the US. In this review, we will discuss the current knowledge on MAFLD and the development of ACLF.

[1]  C. Newberry,et al.  Dietary Approaches for Management of Non-Alcoholic Fatty Liver Disease: A Clinician’s Guide , 2021, Current Gastroenterology Reports.

[2]  Yulin Xiang,et al.  Effect of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis , 2021, Frontiers in Nutrition.

[3]  R. Moreau,et al.  New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. , 2021, Journal of hepatology.

[4]  C. Datz,et al.  Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease , 2021, Hepatology International.

[5]  N. Méndez-Sánchez,et al.  Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases , 2021, Journal of clinical and translational hepatology.

[6]  A. Israni,et al.  OPTN/SRTR 2019 Annual Data Report: Liver , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[7]  S. Terai,et al.  Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database , 2021, Journal of Gastroenterology.

[8]  A. Dhawan,et al.  NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.

[9]  A. Majumdar,et al.  Metabolic associated fatty liver disease: Addressing a new era in liver transplantation , 2020, World journal of hepatology.

[10]  R. Moreau,et al.  The Systemic Inflammation Hypothesis: Towards a New Paradigm of Acute Decompensation and Multiorgan Failure in Cirrhosis. , 2020, Journal of hepatology.

[11]  P. Bork,et al.  Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure , 2020, Nature Reviews Gastroenterology & Hepatology.

[12]  M. Silva,et al.  The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. , 2020, The lancet. Gastroenterology & hepatology.

[13]  Praveen Sharma,et al.  Approach to prevention of non-alcoholic fatty liver disease after liver transplantation. , 2020, Translational gastroenterology and hepatology.

[14]  N. Mahmud,et al.  Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality , 2020, Hepatology.

[15]  N. Borruel,et al.  ALTERATIONS IN GUT MICROBIOME IN CIRRHOSIS AS ASSESSED BY QUANTITATIVE METAGENOMICS. RELATIONSHIP WITH ACUTE-ON-CHRONIC LIVER FAILURE AND PROGNOSIS. , 2020, Gastroenterology.

[16]  A. Canbay,et al.  Patterns and predictors of mortality and disease progression among patients with non‐alcoholic fatty liver disease , 2020, Alimentary pharmacology & therapeutics.

[17]  S. Shreay,et al.  Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database , 2020, EClinicalMedicine.

[18]  F. Bonomini,et al.  Cold Press Pomegranate Seed Oil Attenuates Dietary-Obesity Induced Hepatic Steatosis and Fibrosis through Antioxidant and Mitochondrial Pathways in Obese Mice , 2020, International journal of molecular sciences.

[19]  P. Thuluvath,et al.  Acute-on-chronic liver failure in liver transplant candidates with non-alcoholic steatohepatitis. , 2020, Translational gastroenterology and hepatology.

[20]  S. Wen,et al.  Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis , 2020, Scientific Reports.

[21]  S. Greenberg,et al.  NAFLD Epidemiology, Emerging Pharmacotherapy, Liver Transplantation Implications and the Trends in the United States , 2020, Journal of clinical and translational hepatology.

[22]  Suying Li,et al.  Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data , 2020, Alimentary pharmacology & therapeutics.

[23]  R. Moreau,et al.  Liver Transplantation for Acute‐on‐Chronic Liver Failure: Science or Fiction? , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[24]  N. Chavez-Tapia,et al.  Looking into a new era for the approach of metabolic (dysfunction) associated fatty liver disease , 2020, Annals of Hepatology.

[25]  M. Moriguchi,et al.  Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non‐alcoholic fatty liver disease , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[26]  S. Bollipo,et al.  What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’ , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[27]  S. Taneja,et al.  Nonalcoholic steatohepatitis recurrence after liver transplant. , 2020, Translational gastroenterology and hepatology.

[28]  C. Moylan,et al.  Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C , 2020, Transplantation.

[29]  M. Siddiqui,et al.  Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. , 2020, Gastroenterology clinics of North America.

[30]  L. Henry,et al.  Epidemiology of Non-alcoholic Fatty Liver Disease in North America. , 2020, Current pharmaceutical design.

[31]  A. Sanyal,et al.  MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. , 2020, Gastroenterology.

[32]  Rizwan Ahamed,et al.  Acute exacerbated severe form of nonalcoholic steatohepatitis leading to acute-on-chronic liver failure: A case series , 2020, Indian Journal of Gastroenterology.

[33]  C. Byrne,et al.  Complications, morbidity and mortality of nonalcoholic fatty liver disease. , 2020, Metabolism: clinical and experimental.

[34]  S. Satapathy,et al.  Peri-transplant management of nonalcoholic fatty liver disease in liver transplant candidates . , 2020, Translational gastroenterology and hepatology.

[35]  R. de Cabo,et al.  Effects of Intermittent Fasting on Health, Aging, and Disease. , 2019, The New England journal of medicine.

[36]  R. Mookerjee,et al.  Acute-on-chronic liver failure: definition, prognosis and management , 2019, Frontline Gastroenterology.

[37]  Lanjuan Li,et al.  Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: Classification and regression tree analysis , 2019, Scientific Reports.

[38]  P. Kamath,et al.  Acute on chronic liver failure in non-alcoholic fatty liver and alcohol associated liver disease. , 2019, Translational gastroenterology and hepatology.

[39]  K. Szászi,et al.  Claudin-2: Roles beyond Permeability Functions , 2019, International journal of molecular sciences.

[40]  L. Henry,et al.  Hepatocellular carcinoma and non-alcoholic fatty liver disease , 2019, Hepatology International.

[41]  Monica A. Tincopa,et al.  Incidence and Risks for Non Alcoholic Fatty Liver Disease and Steatohepatitis Post Liver Transplant: Systematic Review and Meta-analysis. , 2019, Transplantation.

[42]  M. Berenguer,et al.  Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. , 2019, Annals of hepatology.

[43]  J. Hodson,et al.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study , 2019, Journal of hepatology.

[44]  Yuan He,et al.  The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation , 2019, International journal of molecular sciences.

[45]  Y. Chawla,et al.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update , 2019, Hepatology International.

[46]  R. Vettor,et al.  Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease , 2019, International journal of molecular sciences.

[47]  P. Kamath,et al.  NASH Is the Most Rapidly Growing Etiology for Acute‐on‐Chronic Liver Failure‐Related Hospitalization and Disease Burden in the United States: A Population‐Based Study , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[48]  Zhaohan Wang,et al.  Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease. , 2019, Clinics and research in hepatology and gastroenterology.

[49]  F. Larsen Artificial liver support in acute and acute-on-chronic liver failure , 2019, Current opinion in critical care.

[50]  H. El‐Serag,et al.  Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. , 2019, Journal of hepatology.

[51]  K. Reddy,et al.  Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[52]  B. Ericzon,et al.  Characteristics and risk factors for recurrence of nonalcoholic steatohepatitis following liver transplantation , 2019, Scandinavian journal of gastroenterology.

[53]  N. Selzner,et al.  Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis , 2019, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[54]  M. Laryea,et al.  Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. , 2019, Transplantation.

[55]  G. Marchesini,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. , 2019, Transplantation.

[56]  G. Svegliati-Baroni,et al.  Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH , 2019, Transplantation.

[57]  A. Panduro,et al.  Current trends of liver cirrhosis in Mexico: Similitudes and differences with other world regions , 2018, World journal of clinical cases.

[58]  K. Tsuneyama,et al.  Gut microbiota translocation promotes autoimmune cholangitis. , 2018, Journal of autoimmunity.

[59]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[60]  P. Kamath,et al.  Grand Rounds: Alcoholic Hepatitis. , 2018, Journal of hepatology.

[61]  J. Trebicka,et al.  EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. , 2018, Journal of hepatology.

[62]  Wesley J. Marrero,et al.  Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States , 2019, Hepatology.

[63]  M. A. Khan,et al.  Clinical epidemiology and disease burden of nonalcoholic fatty liver disease , 2017, World journal of gastroenterology.

[64]  Y. Chawla,et al.  Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models , 2017, Hepatology International.

[65]  A. Sanyal,et al.  Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis , 2017, Transplantation.

[66]  A. McCullough,et al.  Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation , 2017, European journal of gastroenterology & hepatology.

[67]  E. Gorospe,et al.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. , 2017, Gastroenterology.

[68]  R. Moreau,et al.  Acute-on-chronic liver failure: an update , 2017, Gut.

[69]  P. Kamath,et al.  Time trends in the health care burden and mortality of acute on chronic liver failure in the United States , 2016, Hepatology.

[70]  P. Wilmes,et al.  A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility , 2016, Cell.

[71]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[72]  P. Kamath,et al.  Acute-on-chronic liver failure in cirrhosis , 2016, Nature Reviews Disease Primers.

[73]  A. Diehl,et al.  Nonalcoholic Fatty Liver Disease and the Gut Microbiome. , 2016, Clinics in liver disease.

[74]  L. Adams,et al.  International Journal of Molecular Sciences the Natural Course of Non-alcoholic Fatty Liver Disease , 2022 .

[75]  X. Qi,et al.  Child-Pugh, MELD, and ALBI scores for predicting the in-hospital mortality in cirrhotic patients with acute-on-chronic liver failure , 2016, Expert review of gastroenterology & hepatology.

[76]  C. Moylan,et al.  Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation , 2016, Digestive Diseases and Sciences.

[77]  Yi Shen,et al.  Survival Benefits With Artificial Liver Support System for Acute-on-Chronic Liver Failure , 2016, Medicine.

[78]  I. Bergheim,et al.  Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. , 2015, The Journal of nutritional biochemistry.

[79]  A. de Gottardi,et al.  Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis , 2015, Hepatology.

[80]  S. Rensen,et al.  The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation , 2015, Hepatology International.

[81]  C. Streba,et al.  Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. , 2015, World journal of gastroenterology.

[82]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[83]  H. Yoshiji,et al.  Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model , 2014, Molecular medicine reports.

[84]  G. Szabo Gut-liver axis in alcoholic liver disease. , 2015, Gastroenterology.

[85]  N. Milić,et al.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. , 2014, World journal of gastroenterology.

[86]  J. Dumortier,et al.  Recurrent or de novo nonalcoholic fatty liver disease after liver transplantation: Natural history based on liver biopsy analysis , 2014, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[87]  Donghee Kim,et al.  Epidemiology of Nonalcoholic Fatty Liver Disease , 2014 .

[88]  N. Chavez-Tapia,et al.  The prevalence of nonalcoholic fatty liver disease in the Americas. , 2014, Annals of hepatology.

[89]  E. Elamin,et al.  Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[90]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[91]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[92]  N. Chavez-Tapia,et al.  Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. , 2013, Annals of hepatology.

[93]  P. Kamath,et al.  Acute-on chronic liver failure. , 2012, Journal of hepatology.

[94]  C. Vagianos,et al.  Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability , 2012, European journal of clinical investigation.

[95]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[96]  K. Reddy,et al.  Immune dysfunction and infections in patients with cirrhosis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[97]  Baoli Zhu,et al.  Characterization of fecal microbial communities in patients with liver cirrhosis , 2011, Hepatology.

[98]  B. Nemes,et al.  Examination of claudin-1 expression in patients undergoing liver transplantation owing to hepatitis C virus cirrhosis. , 2011, Transplantation proceedings.

[99]  G. Klintmalm,et al.  Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[100]  P. Portincasa,et al.  Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[101]  N. Chavez-Tapia,et al.  Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. , 2005, Annals of hepatology.

[102]  M. Uribe,et al.  Etiology of liver cirrhosis in Mexico. , 2004, Annals of hepatology.

[103]  J. Aparicio,et al.  Intestinal permeability is increased in patients with advanced cirrhosis. , 2003, Hepato-gastroenterology.

[104]  G. Jacquemin [Nonalcoholic steatohepatitis: a review]. , 2003, Revue medicale de Liege.

[105]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .